NCT00666575 - A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness | Biotech Hunter

Enrollment

2,105

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

May 31, 2005

Conditions

Transient Insomnia

Interventions

DRUG

Gabapentin

Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days

DRUG

Placebo

Matched placebo oral capsule 30 minutes prior to bedtime for 28 days

Trial Locations (23)

30328

Pfizer Investigational Site, Atlanta

32720

Pfizer Investigational Site, DeLand

33024

Pfizer Investigational Site, Pembroke Pines

33409

Pfizer Investigational Site, West Palm Beach

33765

Pfizer Investigational Site, Clearwater

34652

Pfizer Investigational Site, New Port Richey

36608

Pfizer Investigational Site, Mobile

37203

Pfizer Investigational Site, Nashville

46250

Pfizer Investigational Site, Indianapolis

76135

Pfizer Investigational Site, Fort Worth

78205

Pfizer Investigational Site, San Antonio

78229

Pfizer Investigational Site, San Antonio

78705

Pfizer Investigational Site, Austin

83704

Pfizer Investigational Site, Boise

83712

Pfizer Investigational Site, Boise

84088

Pfizer Investigational Site, West Jordan

84102

Pfizer Investigational Site, Salt Lake City

85018

Pfizer Investigational Site, Phoenix

87505

Pfizer Investigational Site, Santa Fe

89104

Pfizer Investigational Site, Las Vegas

89128

Pfizer Investigational Site, Las Vegas

90211

Pfizer Investigational Site, Beverly Hills

94102

Pfizer Investigational Site, San Francisco

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY